From GlobeNewswire: 2025-01-17 17:24:36

Lifecore Biomedical, Inc. (NASDAQ: LFCR) plans to hold a special meeting on April 10, 2025, to consider a proposal to approve the issuance of shares of Common Stock upon conversion of Convertible Preferred Stock. The proposal aims to eliminate the current limit on the number of shares the Convertible Preferred Stock can be converted into, allowing for potential conversion beyond the current cap of 19.99% of outstanding Common Stock shares. The maximum number of shares the Convertible Preferred Stock can currently be converted into is 6,056,284 shares.

Holders of record of Lifecore’s Common Stock and Convertible Preferred Stock as of February 18, 2025, will be entitled to vote at the Special Meeting. Lifecore plans to file a preliminary proxy statement with the SEC for the meeting, with a definitive proxy statement to follow. The meeting date and participation details will be included in the Definitive Proxy Statement.

In connection with the Special Meeting, Lifecore will file proxy materials with the SEC, including a preliminary and definitive proxy statement. Shareholders are urged to read all relevant documents for important information about the meeting and the proposal. Lifecore and its directors, officers, and employees may be deemed participants in the solicitation of proxies from stockholders. Information about participants will be provided in the proxy statements.



Read more at GlobeNewswire: Lifecore Biomedical Announces Special Stockholder Meeting